Market Access Blog

Market access in China: tackling challenges in a changing environment

A complex system of shared responsibilities between government bodies and frequent changes to the legislative environment due to ongoing healthcare reforms make China a challenging region for achieving market access. However, the reforms also give reason for optimism that China will shift from an opaque system to a transparent and predictable direction that can be more easily navigated by pharmaceutical companies launching new products in the region.

Focus on Ireland: HTA timeframes and reimbursement

One of the biggest challenges of Market Access in Ireland is the unpredictable timeframe of the HTA process and delays in funding due to a very limited government drug budget.

To help our members understand the real-world timeframes between the initial rapid review submission and reimbursement, and for the various stages of the full HTA process, the MAP Online team conducted a pilot study of 12 drugs which have completed a National Centre for Pharmacoeconomics (NCPE) appraisal and have been reimbursed by the Health Service Executive (HSE) between 2019 and 2021.

Arrow Vector-Quotes